Blood Propofol Concentrations in Children During Spinal Surgery
Comparison of Measured Versus Predicted Blood Propofol Concentrations During Total Intravenous Anaesthesia in Children Undergoing Spinal Surgery
During major spinal surgery evoked potential monitoring is performed to detect spinal cord damage. Intra-venous anaesthesia is the preferred anaesthetic technique because volatile anaesthetic agents supress the evoked potentials. Total Intra-Venous Anaesthesia (TIVA) with propofol is commonly administered as a Target Controlled Infusion (TCI). The TCI is an automated drug delivery system which administers propofol to achieve a desired blood concentration, based on an in built pharmaco-kinetic data (TCI model) derived from previous studies. The TCI model also provides a real time predicted blood concentration to facilitate the anaesthetist to adjust the target concentration of propofol.
The TCI algorithm is based on pharmaco-kinetic data derived from previous studies in a relatively small number of patients, by a "best fit" relationship between blood levels, infusion rates and other factors (such as age and weight). Several factors make it possible for a wide discrepancy between the predicted and the true blood concentrations. This difference can be higher in children compared to adults. Also blood loss and administration of large volumes of intravenous fluids can affect the blood concentrations. This study aims to identify the difference between the predicted and true blood concentrations by using Pelorus 1500, a bedside blood propofol measurement device, in children undergoing major spinal surgery under TIVA.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
London, Royaume-Uni, WC1N 3JH
- Great Ormond Street Hospital for Children NHS Trust
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Children undergoing major spinal surgery under propofol TCI
- Surgery expecting to last more than 3 hours.
Exclusion Criteria:
- Major hepatic or renal disease
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Single arm
The intervention in this study involves taking blood sample from an existing arterial line for measurement of blood propofol levels.
The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models (Paedfusor and Marsh models).
The dose range is usually between a target concentration of 3-8 mcg/ml.
However the anaesthetic management is not changed for the study.
The blood concentrations of propofol will be measured using Pelorus 1500 (Sphere Medical, UK), a CE marked device.
The anaesthetist will be blinded from the measurements, unless the measured value was outside the safe limit ( < 3 mcg/ml or > 10mcg/ml).
|
a bedside blood propofol measurement device
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
The absolute difference between the measured and predicted concentrations of propofol in micrograms per ml of blood.
Délai: Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Median Performance Error (MDPE)
Délai: Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
The median value of ratio between the measured and predicted concentration of propofol to the predicted concentration (Performance error) in blood.
Expressed as a percentage.
This is a measure of overall bias of the target controlled infusion.
|
Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
|
Median Absolute Performance Error (MDAPE)
Délai: Up to 5 hours during the maintenance phase of anaesthesia
|
The median value of the ratio of the absolute difference (excluding the sign) between the measured and predicted concentrations to the predicted concentration (Absolute performance error) in blood.
Expressed as percentage.
This is a measure of the accuracy of the target controlled infusion.
|
Up to 5 hours during the maintenance phase of anaesthesia
|
|
Wobble
Délai: Up to 5 hours during the maintenance phase of anaesthesia
|
The median value of the difference between the individual performance errors and the Median Performance Error (MDPE).
This is a measure of the distribution of the performance errors around the median.
|
Up to 5 hours during the maintenance phase of anaesthesia
|
|
Divergence
Délai: Up to 5 hours during the maintenance phase of anaesthesia
|
The median of the regression coefficient of the performance error against time.
This is a measure of how the target controlled infusion performs with time.
|
Up to 5 hours during the maintenance phase of anaesthesia
|
Collaborateurs et enquêteurs
Les enquêteurs
- Directeur d'études: Michael RJ Sury, FRCA PhD, Great Ormond Street Hospital for Children NHS Foundation Trust
- Chercheur principal: Selvakumar Panchatsharam, MBBS FRCA, Great Ormond Street Hospital for Children NHS Foundation Trust
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 12AR04
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .